Global Softgel Capsules Market Size is Estimated to Reach USD 14.86 billion by 2030, Growing at a CAGR of 7.81 percent Straits Research
| CTLT Stock | USD 63.10 0.14 0.22% |
Slightly above 55% of Catalent's investor base is interested to short. The analysis of overall sentiment of trading Catalent stock suggests that many investors are impartial at this time. Catalent's investing sentiment can be driven by a variety of factors including economic data, Catalent's earnings reports, geopolitical events, and overall market trends.
Catalent |
The increasing prevalence of chronic diseases would increase the demand for softgel capsules for patient treatment. Consequently, boosting the availability of novel softgel capsules in emerging economies through developing innovative products will drive market expansion during the forecast period.New York, United States, March 07, 2024 -- Softgel capsules dissolve more quickly in gastric fluids than a hard gelatin capsules because they contain liquid, semisolid, or solid medicat
Read at finance.yahoo.com
 |
Catalent Fundamental Analysis
We analyze Catalent's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalent using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalent based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Catalent is rated second in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Catalent Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Catalent stock to make a market-neutral strategy. Peer analysis of Catalent could also be used in its relative valuation, which is a method of valuing Catalent by comparing valuation metrics with similar companies.
Peers
Catalent Related Equities
| AMPH | Amphastar | 3.08 | ||||
| EBS | Emergent Biosolutions | 2.68 | ||||
| ALVO | Alvotech | 1.04 | ||||
| BHC | Bausch Health | 0.92 | ||||
| HLN | Haleon Plc | 0.83 | ||||
| ITCI | Intracellular | 0.05 | ||||
| CTLT | Catalent | 0.22 | ||||
| TAK | Takeda Pharmaceutical | 0.37 | ||||
| NBIX | Neurocrine Biosciences | 0.62 | ||||
| TEVA | Teva Pharma | 1.66 |
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.